Bristol-Myers Squibb (NYSE:BMY) trades down 1.3%

Shares of Bristol-Myers Squibb ( NYSE:BMY – Get Free Report ) fell 1.3% on Friday. The company traded as high as $41.79 and last traded at $41.83. 2,888,134 shares traded hands during trading, down 82% from the average session volume of 15,648,693 shares. Shares previously closed at $42.39.

The Wall Street analyst weighs in

A number of research firms have commented on BMY. Wells Fargo & Company upped their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. Barclays decreased their target price on shares of Bristol-Myers Squibb from $43.00 to $41.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 10th. BMO Capital Markets cut their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 27th. Finally, William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $59.07, according to MarketBeat.

Read our latest analysis of BMY

Bristol-Myers Squibb Stock Performance

The stock’s 50-day moving average is $41.68 and its 200-day moving average is $47.02. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99, and a current ratio of 1.11. The firm has a market cap of $86.44 billion, a P/E ratio of -13.75, a PEG ratio of 15.46 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s revenue for the quarter was up 4.7% on a year-over-year basis. In the same quarter in the previous year, the business posted EPS of $2.05. On average, research analysts predict that Bristol-Myers Squibb will post 0.55 earnings per share for the current year.

Bristol-Myers Squibb announces dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be given a $0.60 dividend. This represents a dividend of $2.40 on an annualized basis and a yield of 5.63%. The ex-dividend date is Friday, July 5. Bristol-Myers Squibb’s payout ratio is currently -77.42%.

Bristol-Myers Squibb Institutional Trading

Several hedge funds and other institutional investors have recently modified their holdings of the company. ESL Trust Services LLC purchased a new stake in Bristol-Myers Squibb in the first quarter valued at approximately $27,000. Northwest Financial Advisors acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $27,000. Accordant Advisory Group Inc bought a new stake in shares of Bristol-Myers Squibb in the first quarter worth $31,000. Pacific Capital Wealth Advisors Inc. purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at $34,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter valued at $40,000. Institutional investors and hedge funds own 76.41% of the company’s shares.

About Bristol-Myers Squibb

(Get a free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

See also

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.